Unlock the potential of nasal drug delivery for Central Nervous System (CNS) therapies in this expert-led webinar. With increasing focus on non-invasive routes and the promise of direct nose-to-brain transport, the nasal pathway presents both exciting opportunities and complex challenges. We’ll explore the strategic considerations behind developing drug products for CNS delivery via nasal routes—focusing especially on the critical role of device selection. Attendees will learn how spray pattern, droplet size, and dosing precision can significantly affect drug deposition within the nasal cavity and influence therapeutic effectiveness, particularly in targeting the olfactory region.
The discussion will delve into the importance of harmonising formulation properties with device capabilities to improve bioavailability, stability, and patient adherence. Whether dealing with liquid or dry powder formulations, understanding the nuances of device compatibility is key to overcoming physiological barriers like the blood-brain barrier. We’ll present strategies that integrate formulation science with engineering insights to create viable, efficient nasal dosage forms. Practical device testing methodologies will be examined highlighting how these tools generate data to support robust regulatory submissions and product development decisions.
You’ll gain a comprehensive understanding of the benefits and challenges of Nose-to-Brain (N2B) delivery, including key delivery targets and transport mechanisms. The session will provide a clear view of how smart device selection, paired with tailored formulation development approaches, can unlock more consistent and effective CNS delivery outcomes. Join us to discover how to accelerate your nasal drug development pathway from pre-clinical to market.
Unlock the potential of nasal drug delivery for Central Nervous System (CNS) therapies in this expert-led webinar. With increasing focus on non-invasive routes and the promise of direct nose-to-brain transport, the nasal pathway presents both exciting opportunities and complex challenges. We’ll explore the strategic considerations behind developing drug products for CNS delivery via nasal routes—focusing especially on the critical role of device selection. Attendees will learn how spray pattern, droplet size, and dosing precision can significantly affect drug deposition within the nasal cavity and influence therapeutic effectiveness, particularly in targeting the olfactory region.
The discussion will delve into the importance of harmonising formulation properties with device capabilities to improve bioavailability, stability, and patient adherence. Whether dealing with liquid or dry powder formulations, understanding the nuances of device compatibility is key to overcoming physiological barriers like the blood-brain barrier. We’ll present strategies that integrate formulation science with engineering insights to create viable, efficient nasal dosage forms. Practical device testing methodologies will be examined highlighting how these tools generate data to support robust regulatory submissions and product development decisions.
You’ll gain a comprehensive understanding of the benefits and challenges of Nose-to-Brain (N2B) delivery, including key delivery targets and transport mechanisms. The session will provide a clear view of how smart device selection, paired with tailored formulation development approaches, can unlock more consistent and effective CNS delivery outcomes. Join us to discover how to accelerate your nasal drug development pathway from pre-clinical to market.
By ticking this box, you consent to receiving communications from Upperton related to this topic and other products or services within their portfolio;